Skip to Main Content (Press Enter)

Logo UNITO
  • ×
  • Home
  • Pubblicazioni
  • Progetti
  • Persone
  • Competenze
  • Settori
  • Strutture
  • Terza Missione

UNI-FIND
Logo UNITO

|

UNI-FIND

unito.it
  • ×
  • Home
  • Pubblicazioni
  • Progetti
  • Persone
  • Competenze
  • Settori
  • Strutture
  • Terza Missione
  1. Pubblicazioni

Nrf2 role in the BRAFi/MEKi acquired resistance in melanoma

Abstract
Data di Pubblicazione:
2023
Abstract:
Introduction Melanoma is one of the most aggressive cancers with the poorest prognosis. However, the use of specific inhibitors towards mutant BRAF (BRAFi) and MEK (MEKi) in BRAF-mutated patients has significantly improved progression-free and overall survival. Nevertheless, half of the patients still develop resistance within the first year of therapy. Therefore, understanding the mechanisms of BRAFi/MEKi acquired resistance has become a priority for researchers. In these last few years, scientists have focused on the role of NF-E2-related factor 2 (Nrf2), the master regulator of the cytoprotective and antioxidant response, in acquired chemoresistance. Indeed, its expression and activity are upregulated in various cancer types resistant to several chemotherapic drugs. The aim of this study was to evaluate the contribution of Nrf2 in the BRAFi/MEKi acquired resistance in melanoma, as well as the mechanisms of its activity regulation. Material and Methods Starting from BRAF-mutated murine melanoma cell line D4M, we generated three subclones resistant to BRAFi (dabrafenib, D), MEKi (trametinib, T), andBRAFi/MEKi (double resistance, D+T). Then, we evaluated cell viability (MTT test), anchorage-independent cell growth (Sphere Formation and Soft Agar Assays), apoptosis (Annexin V/IP), Cell invasion (Transwell Boyden chamber), angiogenesis (Tube-Formation assay), intracellular oxidative stress (2′-7′-dichlorodihydrofluorescein diacetate, DCF-DA, assay), glutathione (GSH) levels (Ellman's method), gene expression (western blot, real-time PCR), and gene expression inhibition with specific siRNA. Results and Discussions After nine months of continuous treatments with D, T or D+T, we obtained the three resistant subclones. Compared with the sensitive clone, the resistant sublines showed higher resistance to D, T, or D+T treatments and an enhanced ability to anchorage-independent cell growth with increased migrationand angiogenic capacity. These results allowed us to consider these cell lines good models of resistant melanoma cells toward targeted therapies. These cells showed increased oxidative stress and GSH levels. Nrf2 was upregulated at post-translational levels, with the involvement of deubiquitinase 3 (DUB3). Interestingly, Nrf2 or DUB3 inhibition sensitised cells to targeted therapies.ConclusionNrf2 can contribute to the mechanism of targeted resistancein melanoma. A complete understanding of its role can contribute to developing increasingly effective therapies in advanced melanoma.
Tipologia CRIS:
04E-Meeting abstract in rivista
Elenco autori:
M.A.Cucci, M. Grattarola, C. Monge, A. Roetto, C. Dianzani, S.Pizzimenti
Autori di Ateneo:
DIANZANI Chiara
PIZZIMENTI Stefania
ROETTO Antonella
Link alla scheda completa:
https://iris.unito.it/handle/2318/1935910
Link al Full Text:
https://iris.unito.it/retrieve/handle/2318/1935910/1195089/Abstract%20EACR%202023.pdf
Pubblicato in:
MOLECULAR ONCOLOGY
Journal
  • Aree Di Ricerca

Aree Di Ricerca

Settori (9)


LS4_12 - Cancer - (2022)

CIBO, AGRICOLTURA e ALLEVAMENTI - Farmacologia Veterinaria

CIBO, AGRICOLTURA e ALLEVAMENTI - Patologia e malattie degli animali

CIBO, AGRICOLTURA e ALLEVAMENTI - Scienze cliniche veterinarie

MEDICINA, SALUTE e BENESSERE - Epidemiologia

MEDICINA, SALUTE e BENESSERE - Oncologia e Tumori

MEDICINA, SALUTE e BENESSERE - Ricerca Traslazionale e Clinica

MEDICINA, SALUTE e BENESSERE - Trapianti e medicina rigenerativa

SCIENZE DELLA VITA e FARMACOLOGIA - Interazioni tra molecole, cellule, organismi e ambiente
  • Utilizzo dei cookie

Realizzato con VIVO | Designed by Cineca | 25.6.1.0